Diadema Partners’s Rocket Pharmaceuticals RCKT Stock Holding History

Diadema Partners’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-30,579	Closed	-$109K	–	189
2026 Q1	$109K	Buy	+30,579	New	+$122K	0.02%	130

Other funds holding RCKT

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Diadema Partners's RCKT Position: Q2 2026 in Review

Diadema Partners sold out of Rocket Pharmaceuticals (RCKT) in Q2 2026, closing a stake of 30,579 shares — an estimated $109K sold.

Diadema Partners first reported a position in RCKT in Q1 2026 and held it in 1 quarter. The position peaked at $109K in Q1 2026. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

Diadema Partners reported no remaining Rocket Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Diadema Partners sold 30,579 Rocket Pharmaceuticals shares in Q2 2026, an estimated $109K.
Diadema Partners first reported a position in Rocket Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Diadema Partners's Rocket Pharmaceuticals position peaked at $109K in Q1 2026.
180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.